ADFORM
29.9.2020 12:20:14 CEST | Business Wire | Press release
Adform , the only independent global ad management platform covering all aspects of the digital campaign lifecycle, today introduced its new product suite: Adform FLOW. Intuitively designed to make it easier for marketers to plan, buy and activate media, Adform FLOW has everything they need in one easy-to-use platform: DSP, DMP, SSP, DCO and ad server. Through exceptional user experience and enhanced human/machine collaboration, Adform FLOW provides augmented intelligence to amplify business results.
Features of Adform FLOW include:
- Seamless and integrated User Experience, across all aspects of the campaign workflow and all digital media channels
- SaaS technology, which provides increased control and flexibility; including a modular and open API approach, coupled with the ability to control costs through license-based fees
- First-party identity-ready, setup for privacy compliance and a post-cookie world
- Media-neutrality, with no media or data ownership, and therefore no conflicts
Adform research, conducted in partnership with Dynata and surveying more than 1,000 marketers, shows almost three-quarters of modern marketers (74%) want a single dashboard to manage campaigns efficiently, with top benefits cited as data optimisation, cost efficiencies and control.
Now, more than three years in the making and building on Adform’s two decades of innovation, Adform FLOW is enterprise technology built for modern marketing: independent and integrated, giving marketers enhanced control over their own data, that they have not been able to realise through previous solutions. It is configurable, transparent and secure, enabling seamless management of campaigns.
Digital marketers have long struggled with the inefficiencies presented by the myriad of martech and adtech solutions they deploy, and today’s economic realities make the push for efficiency that much more urgent. Some companies have operated within walled gardens; others have sought out best-of-breed technologies and patched together point solutions that fail to work well together. Adform FLOW provides the feature richness of a complex point solution setup, with the scale, ease of use and efficiency of walled gardens.
Samir Shah, Managing Partner – Data, Technology & Programmatic at Zenith said: "I have been impressed at how Adform has continued to develop its platform, the efficiency gains reported are significant. Via their solutions I can see strategic benefits, particularly during a time of complexity in the market being aligned to the future of first-party IDs, and being able to differentiate is key.”
“Modern marketers need a complete solution that is customisable to their particular needs. We are certain that we can add significant value to our clients by enabling them to do more than they've been able to do before,” said Troels Jensen, CEO of Adform. “As the only independent fully integrated marketing platform, Adform offers transparency, privacy, and ownership of data. By addressing these challenges, Adform's clients benefit from Adform FLOW's unique architecture and are able to secure significantly stronger results.”
About Adform
Adform is the only global, independent and fully integrated advertising platform built for modern marketing. Its unique enterprise technology – Adform FLOW – harnesses superior user experience and a scalable, modular and open architecture, to enable seamless management of the whole campaign lifecycle. It provides clients with enhanced control and transparency across their advertising operations, including ownership of all data from their campaigns. Since 2002, Adform has developed technology to enhance human/machine collaboration and deliver augmented intelligence, thereby amplifying business results for its clients around the world.
For more information, please visit: www.adform.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005513/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom